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Trichilemmal cysts (TCs) can occur as sporadic lesions or in
hereditary–familial settings with autosomal dominant transmission. These
entities have not been widely analyzed in their peculiar aspects yet. The
aim of this study was to describe a cohort of patients with diagnosis of
TCs through a clinical and biomolecular characterization, intended to
highlight some effective diagnostic criteria for their identification. Among
149 cases of this study, 24 cases of TCs (16.1%) arose in patients with at
least one first-degree relative with diagnosis of TCs. Peculiar findings
concerning hereditary lesions included the multiple presentation with an
early onset age. On the basis of clinical evaluation, we propose a panel of
clinical and histologic criteria for the diagnosis of hereditary TCs, which
includes: (i) the diagnosis of TCs in at least two first-degree relatives or in
three first- or second-degree relatives in two consecutive generations; (ii)
at least one of the patients with TCs diagnosed <45 years; and (iii) the
diagnosis of multiple or giant (>5-cm lesions) or rare histopathologic
features (proliferating and ossifying) TCs.
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Trichilemmal cysts (TCs), also called pilar cysts, are
dermal-epithelial cysts originating from the hair follicle
(1, 2). They appear as solitary or multiple intradermal
palpable nodules. Histopathologically, TCs resemble
the external root sheath in the region of the follicular
isthmus. Proliferating and ossifying TCs are rare.
Although the term tricholemma was first introduced by
Headington and French (3), only 6 years later Pinkus
named the portion of the external root sheath between
the bulge and the opening of the sebaceous duct as the
trichilemma.
TCs show a predilection for the scalp (4). The
clinical differential diagnosis includes a wide spectrum
of lesions such as sebaceous and epidermoidal cysts
and cylindromas. The diagnosis is easier when the
clinical examination is integrated with the collection of
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anamnestic personal and familial clinical data, which
sometimes reveal a hereditary setting. Little is known
about the frequency of the hereditary TCs. The first
description of autosomal dominant (AD) TCs was
provided by Munro (4) and Stephens (5). Leppard et al.
reported 115 individuals from 60 families who had TCs;
in 46 of these (77%) an AD pattern of inheritance was
showed (1).
TRICY1 gene mutation status has been investigated
for a pathogenetic role in a Danish family with 38
members, 11 of which affected by TCs (6). The
authors sequenced the two candidate genes previously
reported in inherited hair defects: CTNNB1 and MLH1 ;
however, they failed to detect mutations in exons and
intron–exon bounders.
In this study, we retrospectively reviewed the
histopathologically proven cases of TCs excised at our
Department from 1991 to 2012. We chose to inves-
tigate PTCH1 gene because scientific literature had
not provided any peculiar pathogenic evidences for the
involvement of the already studied TRICY1 , CTNNB1
and MLH1 genes; moreover, we had an early clinical
suspicion of cylindromatosis in our first patient who had
a particularly aggressive cutaneous phenotype. Such
phenotype was not related to CYLD gene mutation, so
that we decided to investigate PTCH1 as second choice.
The specific aim was to investigate the frequency of the
hereditary TCs among a series of patients in a single
institution and to try to elucidate the biomolecular back-
ground underlying the TCs hereditary transmission.
Materials and methods
Overall, 149 surgically excised and histologically con-
firmed TCs were retrospectively reviewed by consulting
the archives of the University of Modena.
Family pedigrees were drawn for all probands.
Written informed consent, agreeing to peripheral blood
sampling and genetic analysis, was obtained. Molecular
analysis of PTCH1 was performed. The PTCH1 cDNA
sequence from GenBank was used as a reference
sequence, where the A of the ATG translation initiation
start site represents nucleotide +1. An Institutional
Review Board approval was obtained.
Results
In our archives, we found 149 patients affected by
TCs in a period of 2 decades. The population was
composed of 66 males and 83 females (mean age:
50.1 ± 17.7 years). Among these patients, 76 (51%)
presented multiple TCs and 73 (49%) only single
lesions (Table 1).
At onset, TCs were most commonly found on the
scalp (77.8%), but they also occurred in trunk (8.1%),
limbs (6.7%), face (5.4%), and arms (4.7%). When
located both on the scalp and on the body, the skin over
the TCs presented visible telangiectasia (Fig. 1a,c). The
cysts appeared between the ages of 5 and 93; the age of
onset in females was 46.9 ± 16 years, whereas in males
was 52.6 ± 18.6 years (Tables 1 and 2).
Table 1. Clinical features of hereditary trichilemmal cysts (TCs)
patients
Number of
patients (%)
Age
(mean±SD)
Patients diagnosed with TCs 149 (100%) 50.6± 17.7
Female (%) 83 (55.7%) 46.9± 16
Male (%) 66 (44.3%) 52.6± 18.6
Patients diagnosed with a
single TC
73 (49%) 52.9± 17.03
Female (%) 44 (29.5%) 53.5± 17.9
Male (%) 29 (19.4%) 52.2± 15.8
Patients diagnosed with
multiple TCs
76 (51%) 47.3± 18
Female (%) 39 (26.1%) 51.4± 19.4
Male (%) 37 (24.8%) 42.8± 15
TC patients diagnosed with a
familial form
24 (16.1%) 41.5± 17.3
Female (%) 13 (8.7%) 36.2± 16.9
Male (%) 11 (7.4%) 47.3± 16.6
SD, standard deviation.
(a) (b)
(c) (d)
Fig. 1. Clinical appearance of trichilemmal cysts (TCs) in the probands
of families with hereditary TCs: (a) A proband’s Pedigree; (b and c) B
proband’s Pedigree; and (d) C proband’s Pedigree.
Twenty-four cases of TCs (16.1%) arose in patients
with at least one first-degree relative with diagnosis
of TCs. The age of onset was lower in women
with a TCs familiar history than in sporadic cases
(Table 3). As regards the number of cysts occurring
in familial settings, more than half of the patients
showed a single lesion (62.5%) and multiple cysts
were reported more frequently among men. Compared
to their sporadic counterpart, we noticed a younger
age of onset and the presence of multiple TCs
among hereditary cases, whereas we did not find a
peculiar body site involvement that could help in
differentiating familial and sporadic cysts (Table 1).
Two patients with a clinical history for familial TCs
showed associated malignancies: the first patient was
affected by colorectal adenocarcinoma and melanoma,
whereas the second one by a renal cell carcinoma and
prostate adenocarcinoma.
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Table 2. Anatomical area involved in trichilemmal cysts (TCs)
development
First TCs
(% patients)
Second TCs
(% patients)
Third TCs
(% patients)
Anatomical area
Sculp 116 (77.8%) 7 (4.7%) 2 (1.3%)
Trunk 12 (8.1%) 2 (1.3%) 0
Lower extremity 10 (6.7%) 0 0
Face 8 (5.4%) 0 1 (0.7%)
Upper extremity 7 (4.7%) 1 (0.7%) 0
Table 3. Characteristics of patients with a familial inheritance of
trichilemmal cysts (TCs)
Patients with a
single TC
Patients with
multiple TCs
TCs patients affected
by a familial form (%)
15 (10.1%) 8 (5.4%)
Age (mean±SD) 42.3±19.9 40.1± 13
Female affected by
familial form (%)
10 (6.7%) 3 (2%)
Age (mean±SD) 37.1±18.2 35± 15.6
Male affected by
familial form (%)
5 (3.4%) 6 (4%)
Age (mean±SD) 52.8±20.8 42.7± 12.2
SD, standard deviation.
Pedigree A
The proband (II.1), a 49-year-old Caucasian male,
had multiple lesions of the scalp. Histopathological
examination revealed TCs. The proband referred that
his father too (I.1, Fig. 2) presented giant TCs of the
scalp.
PTCH1 gene sequencing revealed a novel and rare
germline PTCH1 variant (exon 23; R1297Q) that we
do not found in 350 control individuals. This PTCH1
variant was detected neither in the father’s cyst nor in
the mother’s vulvar squamous cell carcinoma. Hence,
it may not be responsible for the genetic mechanism
involved in the development of TC (Fig. 3).
Pedigree B
The proband (III.1 Pedigree B), a 17-year-old female,
presented with TCs on her face arisen at the age of
12. Her mother (II.2), aged 59 years, had TCs on her
shoulder and arm and her grandfather (I.1) had a TC
on his scalp.
Pedigree C
The proband (III-1), a 27-year-old female, had TCs on
her scalp. Her brother (III.2), her mother (II.2), and her
grandmother (I.2) all had TCs on the scalp. The PTCH1
variant was not detected.
Pedigree D
The proband (III.2), a 23-year-old female, had a TC on
the left arm since the age of 18. Her mother (II.2) had
one on her abdomen and multiple on the scalp.
Pedigree E
The proband (III.1), a 34-year-old female, showed TCs
on her scalp and face. Her mother (II.2) had TCs on
the scalp and neck.
Pedigree F
The proband (III.1), a 50-year-old female, developed
TCs on her scalp at the age of 24. Her uncle (II.1) and
her grandfather (I.1) had giant TCs on the scalp. Her
parents (II.2 and II.3) did not show TCs. The PTCH1
variant was not detected.
Pedigree G
The proband (III.1), a 63-year-old male, presented with
several (>40) TCs on his scalp and arms. His mother
also (II.3) showed TCs on the arms. The PTCH1 variant
was not detected.
Discussion
The familial character of TCs is unknown to most
physicians, and the only genetic studies performed in
the past failed to detect peculiar mutations associated
to this hereditary disorder (6). The two main new
evidences of this study are as follows: first, the
assessment of the incidence of hereditary TCs cases
among a consecutive cohort of apparently sporadic TCs
patients; second, exon 23 PTCH1 variant appears rather
uncommon in TCs development.
At present, the diagnosis of a ‘hereditary trichilem-
mal cysts syndrome’ relies on a list of not well-defined
criteria. Beyond the classical HTC syndrome, TCs can
occur in the familial occurrence of total leukonychia,
TCs and ciliary dystrophy with dominant autosomal
pattern of inheritance (FLOTCH) syndrome (7) and
in type 2 segmental manifestation of multiple glomus
tumors in which the giant TCs show a linear distribu-
tion on the scalp (8). Hence, it is important to evaluate
the clinical features associated to TCs in order to clarify
the clinical background of the potential TCs hereditable
disorder. An accurate clinical classification is also use-
ful for the recruitment of a cohort of homogeneous TCs
patients, which allows the investigation of the genetic
mechanisms underlying an AD transmission.
Leppard et al. reported an AD transmission of
the cutaneous cystic phenotype in 46 of their 60
(77%) families with hereditary TCs (1); among the
14 probands with negative family history, 5 had no
knowledge of other members of their families.
In our study, we detected 16.1% patients with TCs
that presented also one first-degree or two second-
degree relatives affected by the same skin lesions.
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Pedigree A Pedigree B Pedigree C Pedigree D
I 1
1
1 1 12
2
222
II
*
1
1
1
1 1
1
2
2
3
2
2
2
2
3
III
Male unaffedtedPedigree F
Female unaffected
Deceased
I
Pedigree E Pedigree G
1 12 2
Female affected 
by Trichilemmal Cysts
II
Twins
1 2
2
2 23 3 41
1
1
3
3
Male affected 
by Trichilemmal Cysts
* PTCH1 gene carrier
III
22 32 3 4 11 1
Fig. 2. Seven families with hereditary trichilemmal cysts. The arrows indicate the proband.
Fig. 3. Electropherogram of the detected PTCH1 variant (exon 23; R1297Q).
This could imply that patients presenting unusual TCs,
especially when diagnosed at early age, should be
carefully checked to discover underlying an unknown
hereditary susceptibility. We believe that the true
incidence of the syndrome may be underestimated
because of the benign nature of the lesions and the
absence of a careful reconstruction of the pathological
family anamnesis.
We propose a panel of clinical criteria for the
identification of hereditary TC cases, which includes: (i)
the diagnosis of TCs in at least two first-degree relatives
or in three first- or second-degree relatives in two
consecutive generations; (ii) at least one of the patients
with TCs diagnosed <45 years; and (iii) the diagnosis
of multiple or giant (>5 cm) or rare histopathologic
features (proliferating and ossifying) TCs.
The critical role of the early onset age of TCs
is shown in our study, in which 14 of 17 (82%)
TCs probands aged <30 years and 27 of 55 (49%)
probands aged <45 years reported a positive family
history for TCs; this is confirmed by the observation of
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the incidence of the positive family history in probands
aged >45 years at the diagnosis (13%).
The clinical suspicion of hereditary setting allows
early diagnosis and screening of these skin neoplasms
even in young family members; in fact, sporadic TCs
usually occur in elderly individuals. An early detection
permits to avoid the risk of malignant transformation
that is usually high in the context of giant TCs (8).
The PTCH1 variant associated to our first TC
familial case is interesting because it is not present
in any 350 unrelated healthy Italian subjects. A
peculiar genotype–phenotype correlation for PTCH1
gene is not known, because all known mutations
are located in most exons and spread all over the
PTCH1 gene (9). The exon 23 of the PTCH1 has
been rarely involved in the pathogenesis of nevoid
basal cell carcinoma syndrome (NBCCS); the only
exon 23 mutation reported (R1319H) (10) is in the last
intracellular C-terminal domain of PTCH1 , which was
identified as an important regulatory region essential for
proper signaling of Sonic Hedgehog (HH) or PTCH1 .
Literature has already reported that the involvement
of CGG triplet repeat-number polymorphism (CGG8)
alleles in the 5′-untranslated region of PTCH1 was sig-
nificantly higher in the ameloblastoma (AML) patients,
indicating a possible relationship between the CGG8
allele in PTCH1 and the risk for AML. This PTCH1
variant in patients with AMLs was not showed to be
a pathogenic factor for cancerogenesis (11). In addi-
tion, Pro 1315Leu polymorphism might modulate the
association between the use of oral contraceptives and
breast cancer risk (12). It appears that the deletion of
the last 156 amino acids is responsible for the alteration
of HH signaling with a consequent reduction of its tar-
get genes. Mutational status of codon 1315 was further
analyzed to evaluate its association with non-melanoma
skin cancer and might be in linkage disequilibrium with
other polymorphisms (13). A French study reported
the role of PTCH1 exon 23 polymorphism c.3944C4T
in the development of sporadic BCC (14). Concern-
ing sporadic trichoblastomas, no studies have showed
a significant contribution of PTCH1 mutations in their
pathogenesis, so that their genetic background remains
debatable (15).
TCs may be present in hereditary–familial settings,
and in such cases they are multiple, with early age of
onset and contemporary occurring in two or more first-
or second-degree relatives. On the basis of these clinical
evaluation, we propose three clinical and histologic
criteria that would allow identification of autosomal
dominantly inherited TCs. Further studies are required
to validate the potential role of PTCH1 in the cyst
formation both in the sporadic and hereditary setting.
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